Retatrutide evidence correction
September 19, 2026 · Website v4.3.3 / Evidence Map v1.2
Added the published 2025 phase 2 body-composition substudy in adults with type 2 diabetes. Fat- and lean-mass evidence ratings changed from 0/5 to 3/5; function benefit remains 0/5. The earlier review scope omitted this study.
The card, directory, comparison table and PDF now include the composition evidence and its limitations. This is evidence of measured change, not complete muscle preservation.
Evidence updates
September 19, 2026 · Website v4.3 / Evidence Map v1.1
- Added study-specific dose/context sections to all 17 Signal Cards.
- Added apitegromab and eloralintide cards.
- Updated bimagrumab, semaglutide formulations, direct comparison and survodutide references.
- Published the outcome-scoring rubric and revised scores to match the cited evidence.
- Reconciled the public PDF and expanded source-linked coverage.
Study doses describe research, not treatment instructions. Review dates identify an editorial review, not a guarantee that no newer evidence exists.
October 14, 2026 · v5.1 review changes
Added 14 short therapy previews and an Therapy Atlas preview; corrected CagriSema coverage and grade rationale; clarified apitegromab’s indication-specific approval; prepared Evidence Map v1.3 and consistent paid-product review editions.
October 15, 2026: selected evidence corrections
Native MOTS-c maturity is M1 for the reviewed evidence; trial registration is separate from human findings. Selected previews clarify monotherapy, oral versus injected exposure, narrow approvals and community sleep reports. Public accounts remain Tier G and do not earn clinical efficacy points.
October 15, 2026: survodutide source reconciliation
Added the SYNCHRONIZE-2 diabetes publication and acknowledged reported MRI composition findings. Fat and lean scores are NR pending full appraisal, replacing older 0/5 scores. Weight and function scores are unchanged. Separate trial populations and estimands remain explicit.